The Global Market for Biopharmaceutical Bioseparation Systems is Projected to Reach US$11.4 Billion by 2024

Robust Biopharmaceutical Pipeline & Continuous Technology Advancements to Drive Growth in the Global Biopharmaceutical Bioseparation Systems Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Biopharmaceutical Bioseparation Systems market. The global market for Biopharmaceutical Bioseparation Systems is projected to reach US$11.4 billion by 2024, driven by the growing demand for biopharmaceuticals; increased drug development activity; continuous technology advancements; government initiatives aimed at increasing awareness; and growing use of single-use/disposable instruments.

Globally, the market for bioseparation systems is forecast to grow rapidly in the imminent future, driven by the continuous modification of traditional separation methods, as well as availability of new technologies. Chromatography systems, centrifuges, membrane/filters, and other forms of bioseparation systems are used for separation of biological products, such as biopharmaceuticals. Factors, such as growing biopharmaceuticals demand, technological advancements in terms of equipment, and government initiatives aimed at increasing awareness are propelling growth in the global bioseparation systems market. Additionally, the growing use of single-use/disposable instruments spurred by slew of regulations and increasing focus on production efficiency and product quality are driving growth in the market. The development of advanced therapeutics is also creating a favorable scenario for demand growth for separation systems. Furthermore, growing demand for cell-based therapies and personalized medicines would also create strong demand for bioseparation techniques in the years ahead.  However, growth in the market is restrained due to stringent regulations governing bioseparation systems approval, high initial capital cost with respect to bioseparation systems, and the presence of alternative technologies.

While various techniques or systems are available for bioseparation, the market for biopharmaceutical bioseparation systems primarily include chromatography systems, centrifuges, and membranes/filters that represent the most commonly used products that find use in various applications of the bioprocessing chain. Of these, chromatography represents the major technique used in downstream processing of biopharmaceuticals. Advancements are underway in terms of product developments and innovations. Significant emphasis is being placed on optimizing and streamlining existing methods. A key development driving growth in the market is the development of alternatives to Protein A based purification in affinity chromatography. Centrifuges and Filters/ Membranes are however expected to show a higher growth rate in the coming years. While centrifuges are employed for separating macromolecules from solutions and biological particles from suspensions, membranes provide a thin semi-permeable barrier for separating biological materials.

As stated by the new market research report on Biopharmaceutical Bioseparation Systems, the U.S. represents the largest market worldwide, supported by a well-established innovation-driven pharmaceutical industry, continuous development of new biologics, easing regulations on biosimilar drugs and a slew of biological drugs going off-patent. Asia-Pacific and Latin America are poised to drive future growth in the market supported by growing population, increasing demand for better healthcare and launch of new biosimilar drugs. Also, emerging markets such as China, India and Brazil feature a prospering domestic biopharmaceutical industry, with significant expertise and cost benefits attracting investments from leading players.

Major players in the market include 3M Purification Inc., Agilent Technologies Inc., Alfa Wassermann Separation Technologies LLC, Flottweg Separation Technology, GEA Westfalia Separator Group GmbH, GE Healthcare Life Sciences, KNAUER Wissenschaftliche Geräte GmbH, Konik Nanobiotech SL, Merck KGaA, Pall Corporation, ProMetic Life Sciences Inc., Sartorius Stedim Biotech, Repligen Corp., Thermo Fisher Scientific Inc., Tosoh Bioscience Inc., and YMC Europe GMBH, among others.

The research report titled “Biopharmaceutical Bioseparation Systems: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of global companies. The report provides market estimates and projections for Biopharmaceutical Bioseparation Systems in terms of US$ for all major geographic markets, such as the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia, and Rest of Europe), Asia-Pacific (China, India, and Rest of Asia-Pacific), The Middle East & Africa, and Latin America (Brazil and Rest of Latin America). Global market for Biopharmaceutical Bioseparation Systems is also analyzed by the following product segments – Chromatography Systems, and Other Systems (include Centrifuges, and Filters/ Membranes).

For enquiries e-mail us at rsd@strategyr.com or info411@strategyr.com.

To connect with us, visit our LinkedIn page.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.